<DOC>
	<DOCNO>NCT01494610</DOCNO>
	<brief_summary>This comparative bioavailability study compare pharmacokinetics pharmacodynamic effect Fluticasone propionate Salmeterol deliver capsule-based inhaler versus multi-dose dry powder inhaler patient moderate asthma patient moderate severe Chronic obstructive pulmonary disease ( COPD ) . Co-primary endpoint area curve ( AUCτ ) measure plasma Fluticasone propionate ( pharmacokinetic ) pharmacodynamic effect Fluticasone propionate ( weighted mean serum cortisol 0-12h ) last day 10 day study treatment period . Secondary endpoint include follow pharmacokinetic parameter fluticasone propionate salmeterol : AUClast , AUC ( 0-t ) , Cmax , Cmin , tmax , λz , t1/2 well pharmacodynamic effect salmeterol ( pulse rate , blood pressure , electrocardiogram [ ECG ] , potassium glucose ) Fluticasone propionate ( urine cortisol level ) . Safety ( adverse event laboratory abnormality ) also assess secondary endpoint . The study randomise , double blind , double dummy , four-period cross-over study . Approximately 60 asthma COPD patient randomise . Patients meet eligibility criterion receive Fluticasone propionate/salmeterol 250/50mcg bid , capsule-based inhaler multi-dose dry powder inhaler period 10 day randomise order . All patient receive treatment device twice . To maintain double blind , patient receive active treatment placebo time two separate device .</brief_summary>
	<brief_title>Pharmacokinetic Pharmacodynamic ( PK PD ) Study Fluticasone Propionate Salmeterol Combination Product Delivered Capsule-based Inhaler Multi-dose Dry Powder Inhaler Moderate Asthma Patients Moderate Severe Chronic Obstructive Pulmonary Disease ( COPD ) Patients .</brief_title>
	<detailed_description>BACKGROUND This study evaluate comparative bioavailability SERETIDE deliver via establish multi-dose powder inhaler ie DISKUS/Accuhaler new fluticasone propionate/salmeterol capsule-based inhaler . Both formulation deliver 250/50mcg ( microgram ) twice daily ( bid ) dose strength . STUDY RATIONALE The fluticasone propionate/salmeterol capsule-based inhaler develop administration asthma Chronic obstructive pulmonary disease ( COPD ) patient . Therefore , disease population include study . The study assess performance two device respect systemic exposure pharmacodynamic effect . A replicated cross-over design ( four period ) chosen . This design reduce subject number 50 % compare standard 2-period cross-over design . OBJECTIVES Primary Objective -To compare performance fluticasone propionate/salmeterol administer capsule-based inhaler multi-dose dry powder inhaler evaluate fluticasone propionate pharmacokinetic pharmacodynamic endpoint . Secondary Objectives - To compare pharmacokinetic pharmacodynamic effect salmeterol component fluticasone propionate/salmeterol administration capsule-based inhaler multi-dose dry powder inhaler - To compare safety tolerability fluticasone propionate/salmeterol administration capsule-based inhaler multi-dose dry powder inhaler . ENDPOINTS Primary Endpoints - Pharmacokinetic endpoint : AUCτ fluticasone propionate ( area plasma fluticasone propionate concentration-time curve dose interval ) last day study treatment period ( Day 10 ) . - Pharmacodynamic endpoint : Weighted mean serum cortisol 12h last day treatment period ( Day 10 ) . Secondary Endpoints - Pharmacokinetic parameter ( AUClast , AUC ( 0-t ) , Cmax , Cmin , tmax , λz , t1/2 fluticasone propionate salmeterol ) last day treatment period ( Day 10 ) . - Pharmacodynamic parameter : - Fluticasone propionate : Urine cortisol excretion ( 0-24h ) serum cortisol Cmin last day ( Day 10 ) treatment period , - Salmeterol : pharmacodynamic parameter pulse rate , blood pressure , electrocardiogram ( ECG ) , plasma potassium glucose ( weighted mean 0-12h Cmax/Cmin ) last day ( Day 10 ) treatment period - Safety tolerability : Incidence adverse event laboratory abnormality STUDY DESIGN This randomised , four-period cross-over , double-blind , double-dummy study . Patients meet eligibility criterion receive fluticasone propionate/salmeterol 250/50 mcg bid capsule-based inhaler multi-dose dry powder inhaler 10 day per treatment period randomise order . To maintain double blind , patient receive active treatment placebo time two separate device . Patients already inhale corticosteroid ( ICS ) monotherapy combination treatment prior randomization stop exist treatment switch treatment provide study-provided device . The study design compare administration fluticasone propionate/salmeterol two inhalation device , capsule-based inhaler multi-dose dry powder inhaler . Fluticasone propionate/salmeterol administer via multi-dose dry powder inhaler reference product . Fluticasone propionate/salmeterol develop GlaxoSmithKline ( GSK ) capsule-based inhaler administration treatment asthma COPD . TREATMENT ASSIGNMENT Subjects assign one two treatment sequence accordance randomisation schedule Sequence ABBA ( Periods 1 4 ) : A : Fluticasone propionate/salmeterol multi-dose dry powder inhaler ; B : Fluticasone propionate/salmeterol capsule-based inhaler ; B : Fluticasone propionate/salmeterol capsule-based inhaler ; A : Fluticasone propionate/salmeterol multi-dose dry powder inhaler Sequence BAAB ( Periods 1 4 ) : B : Fluticasone propionate/salmeterol capsule-based inhaler ; A : Fluticasone propionate/salmeterol multi-dose dry powder inhaler ; A : Fluticasone propionate/salmeterol multi-dose dry powder inhaler ; B : Fluticasone propionate/salmeterol capsule-based inhaler .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>INCLUSION CRITERIA : ALL PATIENTS : Available duration study able attend clinic study visit . Gender : male female A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 140 pmol/L ) confirmatory ] . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one protocol allow contraception method wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least 24 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method . Childbearing potential agrees use one protocol allow contraception method appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception attend site followup visit . Capable give informed consent , include compliance study requirement restriction list consent form . Body mass index 18 35 kg/m2 inclusive Screening Able use inhaler device adequately train AST ALT &lt; 2xULN ( upper limit normal ) ; alkaline phosphatase bilirubin less equal 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . QT interval correct heart rate ( QTc ) * &lt; 450 millisecond ( msec ) ** QTc &lt; 480 msec patient bundle branch block either QTcB ( QTc Bazzett 's formula ) QTcF ( QTc Fridericia 's formula ) , machine manual overread , male female . The specific formula use study predetermine prior initiation study . The QT correction formula use determine inclusion discontinuation throughout study . base single average QTc value triplicate ECGs obtain brief recording period COPD PATIENTS : Diagnosis : COPD patient , define either Stage III Stage IV COPD diagnosis accord GOLD criterion ( Global Strategy Diagnosis , Management , Prevention COPD , updated 2009 ) [ GOLD , 2009 ] . Individuals must otherwise healthy individual free significant cardiac , gastrointestinal , hepatic , renal , haematological malignancy , endocrine , neurological psychiatric disease determine history , physical examination screen investigation . Age : 4080 year inclusive time signing informed consent . Postbronchodilator force expiratory volume one second ( FEV1 ) &lt; 50 % predict normal value Screening . Patients must abstain short act beta agonist ( SABA ) use 6 hour prior screen visit . Postbronchodilator FEV1/FVC ratio ≤ 0.70 Screening An increase less 15 % baseline FEV1 absolute change &lt; 200ml , 30 minute inhalation 400mcg salbutamol metereddose inhaler ( MDI ) spacer 2.5mg nebuliser Screening . Ex smoker least past 3 month pack history ≥10 pack year [ number pack year = ( number cigarette per day / 20 ) x number year smoke ] . COPD therapy : Patients fluticasone propionate/salmeterol combination 250/50mcg bid via multidose dry powder inhaler prior study allow remain treatment regimen randomization provide eligibility criterion meet . Patients fluticasone propionate/salmeterol combination 250/50mcg bid via meter dose inhaler equivalent dose budesonide/formoterol , 800/24mcg ( total daily dose ) via turbuhaler switch fluticasone propionate/salmeterol combination 250/50mcg bid via GSK provide multidose dry powder inhaler 14 28 day prior randomization . Patients tiotropium addition ICS/LABA ( longacting beta agonist ) treatment ( total daily dose 500mcg fluticasone propionate ICS equivalent eg . 800mcg budesonide ) may continue tiotropium treatment throughout study . Patients tiotropium monotherapy need start treatment fluticasone propionate/salmeterol combination 250/50mcg bid via GSK provide multidose dry powder inhaler 14 28 day prior randomization . They may continue tiotropium treatment throughout study . Patients LABA therapy ( eg . salmeterol 50mcg ) need start treatment fluticasone propionate/salmeterol combination 250/50mcg bid via GSK provide multidose dry powder inhaler 14 28 day prior randomization . ASTHMA PATIENTS : Diagnosis : Patients moderate asthma define Global Initiative Asthma ( GINA ) guideline Screening . A best FEV1 6085 % predict normal value Screening visit . NHANES ( National Health Nutrition Examination Survey ) III predict value use [ Hankinson , 2009 ] . If subject record Hispanic Latino ethnicity , MexicanAmerican equation use ( irrespective race ) . If subject record African American/African Heritage race , African American equation use . If subject record Asian Pacific Islander race , Caucasian formula use conversion factor 0.88 . Otherwise , Caucasian equation use . Age : 18 time signing informed consent . Best clinic screening prebronchodilator FEV1 60 85 % predict normal value ( NHANES III value ) . Patients must abstain SABA use 6 hour prior Screening visit . Asthma therapy : Patients fluticasone propionate/salmeterol combination 250/50mcg treatment via multidose dry powder inhaler prior study allow remain treatment regimen randomization provide eligibility criterion meet . Patients treatment ICS alone ( total daily dose 500mcg fluticasone propionate ICS equivalent eg . 800mcg budesonide ) require switch treatment fluticasone propionate/salmeterol combination 250/50mcg bid via GSK provide multidose powder inhaler 14 28 day prior randomization deem appropriate . Patients treatment budesonide/eformoterol combination ( total daily dose 800/24mcg via Turbuhaler ) require switch fluticasone propionate/salmeterol combination 250/50mcg bid via GSKprovided multidose powder inhaler 14 28 day prior randomization . Patients treatment fluticasone propionate/salmeterol combination dose 250/50mcg bid via meter dose inhaler multidose dry powder inhaler ( eg . 100/50mcg ) require switch fluticasone propionate/salmeterol combination 250/50mcg bid via GSKprovided multidose powder inhaler 14 28 day prior randomization . EXCLUSION CRITERIA : ALL PATIENTS : Any clinically relevant medical condition abnormality identify screen medical assessment procedure , physical examination , laboratory assessment ( include clinical chemistry haematology ) , opinion GSK Medical Monitor likely affect safety subject and/or interfere study procedure outcomes . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody positive HIV test result within 3 month screen . Patients treatment fluticasone propionate either monotherapy combination total daily dose high 500mcg budesonide monotherapy combination total daily dose high 800mcg exclude study Use oral/injectable/depot corticosteroid indication within 3 month prior Screening visit . Use intranasal steroid ( INS ) . To eligible study , patient INS therapy require switch nonINS therapy randomization . Patients abnormal level serum cortisol Screening Abuse alcohol consumption within 12 month Screening visit define follow Australian guideline : Males : An average weekly intake great 21 unit average daily intake great 3 unit . Females : An average weekly intake great 14 unit average daily intake great 2 unit . One unit equivalent 270 mL full strength beer , 470 mL light beer , 30 mL spirit 100 mL wine . A known suspected history drug abuse within 12 month Screening visit . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Where participation study would result donation blood blood product excess 500mL within 56day period . Known hypersensitivity salbutamol ingredient study medication preparation and/or history drug allergy , opinion GSK medical monitor investigator contraindicate participation subject Grapefruit grapefruit juice contain product exclude 2 week prior randomisation collection final blood sample treatment period 4 . Drugs inhibit cytochrome P450 isoform , 3A4 ( CYP3A4 ) , exclude 2 week prior randomisation collection final blood sample treatment period 4 . CYP3A4 inhibitor include cimetidine , clarithromycin , erythromycin , ciprofloxacin , ritonavir , ketoconazole , azole antifungal , complete list provide protocol . Use prescription nonprescription drug , vitamin , herbal dietary supplement , within seven day 5 halflives ( whichever longer ) prior first dose study medication , opinion Principal Investigator , may interfere study outcome . Specifically , calcium vitamin D supplement bisphosphonates allow throughout study . Pregnant female determine positive serum urine βhCG ( βhuman chorionic gonadotropin ) test Screening prior dosing . Patients , , opinion Investigator , able comply protocol requirement . COPD PATIENTS : Subjects respiratory disorder addition COPD ( e.g . bronchiectasis , fibrosis ) significant comorbidity might affect lung function ( e.g . poorly control heart failure , atrial fibrillation ischaemic heart disease ) . Regular oxygen nebulised bronchodilator therapy The subject history respiratory infection ( include sinusitis ) within 4 week prior Screening visit Any previous lung resection surgery ( eg. , lung volume reduction surgery lobectomy ) ASTHMA PATIENTS : Acute exacerbation asthma require hospitalisation 6 week prior Screening visit . Subjects may use inhale tobacco product within past 3 month ( ie . cigarette , cigar pipe tobacco ) historical use 10 pack year ; [ number pack year = ( number cigarette per day / 20 ) x number year smoke ] .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>safety</keyword>
	<keyword>replicate cross-over design</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>Fluticasone propionate/Salmeterol</keyword>
	<keyword>capsule-based inhaler</keyword>
	<keyword>COPD</keyword>
	<keyword>asthma</keyword>
	<keyword>multi dose dry powder inhaler</keyword>
	<keyword>bioavailability</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>